OncoVista Innovative Therapies, Inc., a biopharmaceutical company, develops targeted anticancer therapies by utilizing tumor-associated biomarkers. The company's product candidates include Cordycepin (OVI-123), which is in Phase I/II clinical trials for the treatment of refractory TdT positive leukemias; and L-Nucleoside Conjugates (OVI-117) that is under pre-clinical development for the treatment of colon cancer. The company was founded in 2004 and is based in San Antonio, Texas.
General Outlook
In simple terms, OncoVista Innovative Therapies, Inc. has 5583.37 M shares that people are buying and selling right now.
Stock Prices
OncoVista Innovative Therapies, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.0002, while its low point bottomed out at $0.0002. This variance in figures offers investors a lucid insight into the roller-coaster ride that is OncoVista Innovative Therapies, Inc.'s stock market.
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”